XOMA
XOMA
About Us
Corporate Overview
XOMA is a leading biopharmaceutical company in the field of therapeutic antibody discovery and development. We have a royalty interest in one approved therapeutic antibody, RAPTIVA? (efalizumab), which is marketed in the United States, Europe and elsewhere, for the treatment of moderate-to-severe plaque psoriasis under an agreement with Genentech, Inc. as a result of a prior collaborative product development program. We also have royalty interests in additional therapeutic antibody product candidates being developed by others as a result of licensing our technologies. XOMA?s pipeline includes both proprietary products and collaborative programs at various stages of preclinical and clinical development primarily directed toward treatments for cancer and immune disorders. XOMA has contributed key innovations to the field of therapeutic antibodies. Today we possess an exceptionally broad technology platform for the discovery, optimization and manufacture of therapeutic antibodies as well as a fully integrated product development infrastructure for antibodies and other biologics.
Contract Manufacturing Services
XOMA has proven expertise and a successful partnering track record for custom manufacture of biologic product candidates. We have the technologies, facilities and expertise to seamlessly advance products from preclinical supply through clinical development. We offer the flexibility you require from cell line development to pilot plant scale up and cGMP manufacturing, as well as quality, analytical and regulatory support to meet your program objectives from early stage development through commercial launch.
Please contact Business Development at XOMA for more information on custom contract manufacturing.
BizDevInfo@xoma.com
XOMA Corporate and Research Headquarters:
XOMA (US) LLC
A Subsidiary of XOMA Ltd.
2910 Seventh Street
Berkeley, CA 94710
Phone: (510) 204-7200
Fax: (510) 644-2011
Product and Technology Licensing and Partnerships
Technology licensing inquiries may be sent via email, post or facsimile. Please include informational materials about your company along with a cover letter indicating which of our technologies you are interested in, addressed to:
Attn: Business Development
XOMA (US) LLC
A Subsidiary of XOMA Ltd.
2910 Seventh Street
Berkeley, CA 94710
Phone: (510) 204-7200
BizDevInfo@xoma.com
XOMA is also actively pursuing additional development collaborations with other biopharmaceutical companies. Please contact our Business Development group:
BizDevInfo@xoma.com
Technology & Capabilities
From Antibody Discovery to Product Launch
Through a combination of internal innovation and strategic cross-licensing, XOMA has multiple technologies for antibody discovery, lead selection, optimization and production. XOMA?s fully integrated product development infrastructure pulls antibody products through preclinical sciences to product launch. This unique combination of intellectual property, expertise, and infrastructure positions XOMA to rapidly generate antibody products and deliver them to the market in a time-efficient manner. Partnering with XOMA provides an immediate competitive advantage through access to XOMA?s technologies, expertise, and infrastructure, with the benefits of accelerating product development and realizing financial advantages.
A Leader in Therapeutic Antibodies (PDF)
Biologics Manufacturing (PDF)
Accelerating IND Submission & Clinical Trial Execution (PDF)
Votes:30
Comments: 0